Insider Buying: Orchestra BioMed (NASDAQ:OBIO) Director Buys $82,600.00 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Director Eric Fain acquired 20,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $4.13 per share, for a total transaction of $82,600.00. Following the transaction, the director directly owned 91,709 shares of the company’s stock, valued at approximately $378,758.17. The trade was a 27.89% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.

Orchestra BioMed Trading Down 0.5%

OBIO stock opened at $3.98 on Thursday. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35. Orchestra BioMed Holdings, Inc. has a twelve month low of $2.20 and a twelve month high of $5.42. The stock has a market capitalization of $238.33 million, a price-to-earnings ratio of -4.10 and a beta of 0.52. The firm’s fifty day simple moving average is $4.26 and its two-hundred day simple moving average is $4.27.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The business had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.92 million. As a group, analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.54 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. bought a new position in shares of Orchestra BioMed in the fourth quarter worth about $38,000. Creative Planning purchased a new stake in Orchestra BioMed in the second quarter worth about $40,000. XTX Topco Ltd purchased a new stake in Orchestra BioMed in the second quarter worth about $45,000. Jane Street Group LLC purchased a new stake in Orchestra BioMed in the second quarter worth about $50,000. Finally, Virtu Financial LLC purchased a new stake in Orchestra BioMed in the fourth quarter worth about $57,000. 53.20% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Orchestra BioMed in a research report on Thursday, May 14th. Barclays upped their price target on shares of Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a report on Thursday, March 12th. Weiss Ratings cut shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Finally, Wall Street Zen cut shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Key Stories Impacting Orchestra BioMed

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by insider David Hochman and Director Jason Aryeh. Insider accumulation is often viewed as a signal that management believes the stock is undervalued. SEC filing for Eric Fain purchase
• Positive Sentiment: HC Wainwright reiterated a Buy rating on OBIO and maintained a $10 price target while slightly lifting some earnings estimates, reinforcing Wall Street’s view that the stock has meaningful upside from current levels. Benzinga report
• Positive Sentiment: Orchestra BioMed said management will participate in the Jefferies Global Healthcare Conference, which could increase visibility with investors and potential strategic partners. Conference announcement
• Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating, so the message was mixed rather than outright negative. Benzinga report

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.